狄诺塞麦国内哪里能买到？

(denosumab) is the first approved monoclonal antibody that specifically targets RANK ligand. RANK ligand is a transmembrane or soluble protein that is necessary for osteoclasts to maintain their structure, function, and survival. Its main function in bone is to stimulate the differentiation and activity of osteoclasts and inhibit the apoptosis of osteoclasts. Today we will learn more about where to buy denosumab in China?

In 2018, denosumab (denosumab) entered the rapid review channel of the National Medical Products Administration and is currently the only drug used to treat giant cell tumor of bone. The price of denosumab available in China is relatively expensive, while the Turkish version of denosumab, the American Amgen Xgeva 120mg, is priced around $1,500. Patients in need can go abroad to purchase medicines, or they can obtain medicines through domestic professional overseas medical service organizations (such as Medical Companion Travel) and have them delivered directly to their homes, ensuring they are genuine.

The effect of denosumab (denosumab) on bone reconstruction can be evaluated by measuring some bone renewal markers, such as the bone resorption marker N-telopeptide, the bone formation marker bone-specific alkaline phosphatase, etc. A phase I clinical study conducted in healthy postmenopausal women showed that a dose-dependent decrease in morning urine NTX levels was observed on day 2 after administration. This decrease lasted for 6 months, with the maximum decrease reaching 84% compared with baseline. This effect is reversible. When serum denosumab levels disappear, NTX levels can be seen to rise again, which reflects the reversibility of its effect on bone reconstruction. As treatment continues, these effects will persist for a new cycle.

Denosumab (denosumab) is seen as one of the most important growth drivers for Amgen, the world's largest biotech company. Denosumab, an injectable drug with the chemical name denosumab, is approved to prevent fractures caused by cancer that has spread to bones, not to prevent or delay the spread of cancer.

Denosumab (denosumab) In a clinical trial of 1,432 men with prostate cancer that had stopped responding to hormone therapy, denosumab kept cancer cells from spreading to the bones for a little longer than four months. Amgen said denosumab will be able to treat 50,000 men in the United States whose disease has progressed to this stage.

The above is the content of the purchasing channels for (denosumab), I hope it can help you!